Goldline Pharmaceutical Confirms Nil Deviation in IPO Proceeds Utilization for Sep'26
Goldline Pharmaceutical Ltd 路 Others (Uncategorized) 路 15 Nov 2026, 1:26 am
Goldline Pharmaceutical Confirms Nil Deviation in IPO Proceeds Utilization for Sep'26 Goldline Pharmaceutical Limited reported zero deviation or variation in the utilization of its IPO proceeds for the half-year ended 30th Sep'26. The company raised gross proceeds of INR 1,161.00 Lakhs via an SME IPO on 19th May'26, netting INR 1,006.00 Lakhs. The entire net proceeds were fully utilized per stated prospectus objectives, deploying INR 835.45 Lakhs toward repayment of outstanding borrowings and INR 170.55 Lakhs for general corporate purposes. Both the Audit Committee and statutory auditors confirmed full compliance with no deviations.
Original exchange filing (PDF)
More announcements from Goldline Pharmaceutical Ltd
- Declaration of Un-audited Standalone Financial Results of the company for the half year ended September 30, 2026 路 15 Nov 2026
- Outcome of Board Meeting dated 14th November, 2026 pursuant to Reg 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 & Submission .... 路 15 Nov 2026
- Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve The Standalone Unaudited .... 路 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Laxmikant Mujumdar 路 01 Sept 2026
- Scrutinizer Report 路 31 Aug 2026
- AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26. 路 30 Aug 2026
